Scopus BioPharma, a preclinical biotech developing immuno-oncology gene therapies for cancer, lowered the proposed deal size for its upcoming IPO on Tuesday. The New York, NY-based company now plans to raise $3 million by offering 0.5 million shares at a...read more
Micro-cap oncology biotech Scopus BioPharma prices Reg A+ IPO at $5.50 midpoint
Because...read more
Micro-cap oncology biotech Scopus BioPharma cuts deal size by 50% ahead of $3 million Reg A+ IPO
Scopus BioPharma, a preclinical biotech developing immuno-oncology gene therapies for cancer, lowered the proposed deal size for its upcoming IPO on Tuesday. The New York, NY-based company now plans to raise $3 million by offering 0.5 million shares at a...read more
Micro-cap oncology biotech Scopus BioPharma adds underwriter, sets terms for $6 million Reg A+ IPO
The company originally filed in May 2020 but was ineligible for...read more